ONC212: Potential for patients with pancreatic cancer and leukemias

ONC212 is a dual agonist of the mitochondrial protease ClpP and the G protein-coupled receptor GPR132. Downstream effects of dual target engagement in tumor cell include activation of the integrated stress response, altered mitochondrial bioenergetics and inhibition of pro-survival Ras signaling that ultimately lead to cell death. ONC212 exhibits potent efficacy in several nonclinical oncology models across both solid and hematological malignancies, including pancreatic cancer and leukemias that exhibit high GPR132 and/or ClpP expression.

GLP-toxicology studies have been completed and nonclinical studies are ongoing to identify oncology indications and predictive biomarkers to support clinical development opportunities that are differentiated from other imipridones currently in clinical development.